featured
Maintenance Pembrolizumab After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
J. Clin. Oncol 2020 Jun 01;38(16)1797-1806, MD Galsky, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, LH Dang, DM Geynisman, R Walling, RS Alter, M Kassar, J Wang, S Gupta, N Davis, J Picus, G Philips, DI Quinn, GK Haines, NM Hahn, Q Zhao, M Yu, SK PalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.